Scholarlink

<p>Ershi-wei Chenxiang pills (ECP) are widely acknowledged for their effectiveness in stroke treatment. This study aims to explore the molecular mechanisms of ECP in stroke therapy using network pharmacology and validation experiments. Targets related to ECP and stroke were acquired from an online database, and the intersections of these targets were identified as the potential therapeutic targets for ECP in treating stroke. The protein–protein interaction (PPI) network was established using the STRING database and visualized through the Cytoscape software. The Hiplot online mapping tool was utilized for gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways analysis enrichment analyses, followed by the oebiotech platform for bubble mapping. Ultimately, molecular docking and in vitro cell experiments were conducted to validate the findings. As a result, a total of 82 effective active ingredients, 322 potential targets, and 419 ECP-related targets were screened in the study. The number of common targets between ECP and stroke was 75. PPI analysis showed that the key targets of ECP in treating stroke included ALB, TNF, IL6, VEGFA and MAPK3. Additionally, 2174 GO items and 186 KEGG signaling pathways were obtained from the analysis. The main ingredients and the target proteins exhibited a good binding ability in molecular docking. The cell experiments revealed that ECP might regulate the mRNA expression of ALB, TNF, VEGFA and MAPK3 to participate in the treatment of stroke. In conclusion, this study presents the preliminary understanding of the “multi-ingredient-multi-target-multi-pathway” mechanism of action of ECP in stroke treatment, confirmed through molecular docking and experimental validation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring the Mechanism of Quercetin in Ershi-Wei Chenxiang Pills (ECP) on Stroke Treatment by Network Pharmacology and Experimental Validation

  • 期刊论文

  • 发表日期：

    2025年6月1日

查看全文
  • Ziyi Zhang,
  • Mingyue Chen,
  • Jinpeng Xu,
  • Beibei Zhao,
  • Yijin Qi,
  • Liang Wang,
  • Yemeng Sheng,
  • Xiaoli Liu,
  • Tianbo Jin,
  • Li Wang

摘要

Ershi-wei Chenxiang pills (ECP) are widely acknowledged for their effectiveness in stroke treatment. This study aims to explore the molecular mechanisms of ECP in stroke therapy using network pharmacology and validation experiments. Targets related to ECP and stroke were acquired from an online database, and the intersections of these targets were identified as the potential therapeutic targets for ECP in treating stroke. The protein–protein interaction (PPI) network was established using the STRING database and visualized through the Cytoscape software. The Hiplot online mapping tool was utilized for gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways analysis enrichment analyses, followed by the oebiotech platform for bubble mapping. Ultimately, molecular docking and in vitro cell experiments were conducted to validate the findings. As a result, a total of 82 effective active ingredients, 322 potential targets, and 419 ECP-related targets were screened in the study. The number of common targets between ECP and stroke was 75. PPI analysis showed that the key targets of ECP in treating stroke included ALB, TNF, IL6, VEGFA and MAPK3. Additionally, 2174 GO items and 186 KEGG signaling pathways were obtained from the analysis. The main ingredients and the target proteins exhibited a good binding ability in molecular docking. The cell experiments revealed that ECP might regulate the mRNA expression of ALB, TNF, VEGFA and MAPK3 to participate in the treatment of stroke. In conclusion, this study presents the preliminary understanding of the “multi-ingredient-multi-target-multi-pathway” mechanism of action of ECP in stroke treatment, confirmed through molecular docking and experimental validation.